Lobsor Pharmaceuticals has reported that following Swedish MPA market approval in October 2018, the Swedish Dental and Pharmaceutical Benefits Agency (TLV) has included Lecigon on Sweden’s list of reimbursed drugs.
A major milestone
“This marks a major milestone as Sweden becomes the first country to offer patients this new therapeutic system for symptomatic treatment of Advanced Parkinson’s disease (APD),” said Roger Bolsöy, CEO of Lobsor. “With the new formulation and lightweight delivery pump, we believe Lecigon will significantly improve convenience and quality of life for Parkinson’s patients. Furthermore, the pivotal clinical trial with Lecigon showed the same clinical outcome as current advanced levodopa therapy but with a significantly reduced dose.”
This reimbursement applies to treatment of Advanced Parkinson’s disease *. Lobsor now intends to obtain further market approvals and introduce Lecigon into carefully selected markets throughout Europe over the next 24 months.
* Indication: Severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations of anti-Parkinsonian medicinal products have not given satisfactory results.
Photo of Roger Bolsöy: Lobsor Pharmaceuticals